Cue Biopharma (NYSE: CUE) — Company Overview, News & Financial Data
Cue Biopharma is a biopharmaceutical company developing injectable biologics to modulate T cells for various diseases.

Cue Biopharma
Cue Biopharma (NASDAQ:CUE) is a biopharmaceutical company pioneering the development of a novel class of injectable biologics to selectively engage and modulate target T cells directly within the patient's body. The company's proprietary platform, the Immuno-STAT™ (Selective Targeting and Alteration of T cells) technology, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. Cue Biopharma's strategy focuses on creating safer, more effective therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Their active projects span multiple stages of preclinical and clinical development, aiming to validate the Immuno-STAT platform's versatility and its potential to revolutionize current treatment paradigms by providing targeted, durable, and controllable immune modulation.
Snapshot
Operations
Products and/or services of Cue Biopharma
- Immunotherapies leveraging Immuno-STAT platform for selective modulation of disease-specific T cells in cancer, autoimmune, and chronic infectious diseases.
- CUE-101, a biologic engaging and expanding specific anti-tumor T cells in HPV-driven cancers.
- CUE-102, designed to activate and expand a population of WT1-specific T cells for the treatment of WT1-expressing cancers.
- CUE-201, aimed at addressing autoimmune diseases by selectively modulating disease-specific T cells without general immune suppression.
- Biologics for chronic infectious diseases, focusing on leveraging the immune system for durable viral suppression.
- Partnerships with leading pharmaceutical companies to expand the application of the Immuno-STAT platform across various diseases.
Cue Biopharma executive team
- Lucinda WarrenPrincipal Accounting Officer & Chief Business Officer
- Colin G. SandercockSenior Vice President of Intellectual Property
- Shao-Lee LinPresident, CEO & Director
- Ronald D. Seidel IIICo-Founder
- Rodolfo Jose ChaparroCo-Founder
- Steven C. AlmoCo-Founder and Chairman of Scientific & Clinical Advisory Board
- James M. AhlersChief Financial Officer
- Agnes LeeChief Officer of Public & Investor Relations
- Sumita RayChief Legal & Compliance Officer and Corporate Secretary
- Daniel G. BakerInterim Chief Development Officer
Latest news about Cue Biopharma
Recent announcements
What Cue Biopharma (CUE) has told the market, newest first.
- LULD halt | CUEPrice sensitive
- LULD halt | CUEPrice sensitive
- LULD halt | CUEPrice sensitive
- LULD halt | CUEPrice sensitive
- LULD halt | CUEPrice sensitive
- 10-Q | Cue Biopharma, Inc.
- 8-K | Cue Biopharma, Inc.
- SCHEDULE 13G | Cue Biopharma, Inc.
Key financials
Reported results for Cue Biopharma, in USD.
- Market cap
- 34.7M
- Revenue (TTM)
- 35.6M
- P/E ratio
- —
- EPS (diluted, TTM)
- -27.8
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 27.5M | -26.5M | -26.6M | |
| 9.3M | -41.5M | -40.7M | |
| 5.5M | -52.1M | -50.7M | |
| 1.2M | -53.2M | -53M |